Park Ha Biological Technology is trading 5.67% down at $2.66 amid broad risk-off selling across U.S. markets.
- September 1, 2026 trading has been pressured by Middle East tensions, higher oil prices, rising bond yields, and weaker labor and manufacturing data.
- No new company-specific announcement was identified.
- Recent coverage remains focused on an ongoing shareholder lawsuit; its September 28 deadline is not a new September 1 catalyst.